[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3] BIRD A.DNA methylation patterns and epigenetic memory[J].Genes Dev,2002,16(1):6-21.
[4] BAUSCH B,JILG C,GLASKER S,et al.Renal cancer in von Hippel-Lindau disease and related syndromes[J].Nat Rev Nephrol,2013,9(9):529-538.
[5] KIM W,KAELIN W G Jr.The von Hippel-Lindau tumor suppressor protein:new insights into oxygen sensing and cancer[J].Curr Opin Genet Dev,2003,13(1):55-60.
[6] LINEHAN W M,RUBIN J S,BOTTARO D P.VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma[J].Int J Biochem Cell Biol,2009,41(4):753-756.
[7] MCRONALD F E,MORRIS M R,GENTLE D,et al.CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma[J].Mol Cancer,2009,8:31.
[8] RYDZANICZ M,WRZESINSKI T,BLUYSSEN H A,et al.Genomics and epigenomics of clear cell renal cell carcinoma:recent developments and potential applications[J].Cancer Lett,2013,341(2):111-126.
[9] COSTA V L,HENRIQUE R,DANIELSEN S A,et al.TCF21 and PCDH17 methylation:An innovative panel of biomarkers for a simultaneous detection of urological cancers[J].Epigenetics,2011,6(9):1120-1130.
[10] MORRIS M R,MAHER E R.Epigenetics of renal cell carcinoma:the path towards new diagnostics and therapeutics[J].Genome Med,2010,2(9):59.
[11] RICKETTS C J,MORRIS M R,GENTLE D,et al.Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma[J].Epigenetics,2012,7(3):278-290.
[12] MORRIS M R,RICKETTS C J,GENTLE D,et al.Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma[J].Oncogene,2011,30(12):1390-1401.
[13] HU C Y,MOHTAT D,YU Y,et al.Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival[J].Clin Cancer Res,2014,20(16):4349-4360.
[14] ARAI E,CHIKU S,MORI T,et al.Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas[J].Carcinogenesis,2012,33(8):1487-1493.
[15] BALDEWIJNS M M,van VLODROP I J,SCHOUTEN L J,et al.Genetics and epigenetics of renal cell cancer[J].Biochim et Biophys Acta,2008,1785(2):133-155.
[16] de MARTINO M,KLATTE T,HAITEL A,et al.Serum cell-free DNA in renal cell carcinoma:a diagnostic and prognostic marker[J].Cancer,2012,118(1):82-90.
[17] BENNETT K L,CAMPBELL R,GANAPATHI S,et al.Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma[J].Genes Chromosomes Cancer,2011,50(8):654-661.
[18] LIAO L M,BRENNAN P,VAN BEMMEL D M,et al.LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer[J].PLoS One,2011,6(11):e27361.
[19] QIAN D Z,KACHHAP S K,COLLIS S J,et al.Class Ⅱ histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha[J].Cancer Res,2006,66(17):8814-8821.
[20] NIU X,ZHANG T,LIAO L,et al.The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C[J].Oncogene,2012,31(6):776-786.
[21] DUNS G,van den BERG E,van DUIVENBODE I,et al.Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma[J].Cancer Res,2010,70(11):4287-4291.
[22] DALGLIESH G L,FURGE K,GREENMAN C,et al.Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes[J].Nature,2010,463(7279):360-363.
[23] HAKIMI A A,CHEN Y B,WREN J,et al.Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma[J].Eur Urol,2013,63(5):848-854.
[24] YOSHIKAWA M,HISHIKAWA K,MARUMO T,et al.Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells[J].J Am Soc Nephrol,2007,18(1):58-65.
[25] LIU L,XU Z,ZHONG L,et al.Enhancer of zeste homolog 2(EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma[J].BJU Int,2016,117(2):351-362.
[26] SAKURAI T,BILIM V N,UGOLKOV A V,et al.The enhancer of zeste homolog 2(EZH2),a potential therapeutic target,is regulated by miR-101 in renal cancer cells[J].Biochem Biophys Res Commun,2012,422(4):607-614.
[27] SELIGSON D B,HORVATH S,MCBRIAN M A,et al.Global levels of histone modifications predict prognosis in different cancers[J].Am J Pathol,2009,174(5):1619-1628.
[28] MOSASHVILLI D,KAHL P,MERTENS C,et al.Global histone acetylation levels:prognostic relevance in patients with renal cell carcinoma[J].Cancer Sci,2010,101(12):2664-2669.
[29] ELLINGER J,KAHL P,MERTENS C,et al.Prognostic relevance of global histone H3 lysine 4(H3K4) methylation in renal cell carcinoma[J].Int J Cancer,2010,127(10):2360-2366.
[30] ROGENHOFER S,KAHL P,MERTENS C,et al.Global histone H3 lysine 27(H3K27) methylation levels and their prognostic relevance in renal cell carcinoma[J].BJU Int,2012,109(3):459-465.
[31] HAUSSER J,ZAVOLAN M.Identification and consequences of miRNA-target interactions——beyond repression of gene expression[J].Nat Rev Genet,2014,15(9):599-612.
[32] LIM L P,LAU N C,GARRETT-ENGELE P,et al.Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs[J].Nature,2005,433(7027):769-773.
[33] LEWIS B P,SHIH I H,JONES-RHOADES M W,et al.Prediction of mammalian microRNA targets[J].Cell,2003,115(7):787-798.
[34] ZEN K,ZHANG C Y.Circulating microRNAs:a novel class of biomarkers to diagnose and monitor human cancers[J].Med Res Rev,2012,32(2):326-348.
[35] MITCHELL P S,PARKIN R K,KROH E M,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J].Proc Natl Acad Sci U S A,2008,105(30):10513-10518.
[36] IWAMOTO H,KANDA Y,SEJIMA T,et al.Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma[J].Int J Oncol,2014,44(1):53-58.
[37] REDOVA M,POPRACH A,NEKVINDOVA J,et al.Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma[J].J Transl Med,2012,10:55.
[38] WANG C,HU J,LU M,et al.A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma[J].Sci Rep,2015,5:7610.
[39] MLCOCHOVA H,HEZOVA R,STANIK M,et al.Urine microRNAs as potential noninvasive biomarkers in urologic cancers[J].Urol Oncol,2014,32(1):41.e41-49.
[40] YUN S J,JEONG P,KIM W T,et al.Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer[J].Int J Oncol,2012,41(5):1871-1878.
[41] von BRANDENSTEIN M,PANDARAKALAM J J,KROON L,et al.MicroRNA 15a,inversely correlated to PKCalpha,is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples[J].Am J Pathol,2012,180(5):1787-1797.
[42] ZAMAN M S,SHAHRYARI V,DENG G,et al.Up-regulation of microRNA-21 correlates with lower kidney cancer survival[J].PLoS One,2012,7(2):e31060.
[43] FRITZ H K,LINDGREN D,LJUNGBERG B,et al.The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma[J].Eur J Cancer,2014,50(10):1758-1765.
[44] ZHAO X,ZHAO Z,XU W,et al.Down-regulation of miR-497 is associated with poor prognosis in renal cancer[J].Int J Clin Exp Pathol,2015,8(1):758-764.
[45] ISHIHARA T,SEKI N,INOGUCHI S,et al.Expression of the tumor suppressive miRNA-23b/27b cluster is a good prognostic marker in clear cell renal cell carcinoma[J].J Urol,2014,192(6):1822-1830.
[46] SAMAAN S,KHELLA H W,GIRGIS A,et al.miR-210 is a prognostic marker in clear cell renal cell carcinoma[J].J Mol Diagn,2015,17(2):136-144.
[47] MANGOLINI A,BONON A,VOLINIA S,et al.Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma[J].FEBS Open Bio,2014,4:952-965.
[48] MCCORMICK R I,BLICK C,RAGOUSSIS J,et al.miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer,regulates ISCU and correlates with good prognosis[J].Br J Cancer,2013,108(5):1133-1142.
[49] KHELLA H W,SCORILAS A,MOZES R,et al.Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma[J].Am J Pathol,2015,185(3):693-703.
[50] WOTSCHOFSKY Z,BUSCH J,JUNG M,et al.Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy[J].Clin Chim Acta,2013,416:5-10.
[51] MERCER T R,DINGER M E,MATTICK J S.Long non-coding RNAs:insights into functions[J].Nat Rev Genet,2009,10(3):155-159.
[52] 郭倚天,许斌,陈明.长链非编码RNA在前列腺癌中的作用及研究进展[J].医学研究生学报,2017,30(2):199-203.
[53] ZHANG H M,YANG F Q,CHEN S J,et al.Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma[J].Tumour Biol,2015,36(4):2947-2955.
[54] HIRATA H,HINODA Y,SHAHRYARI V,et al.Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205[J].Cancer Res,2015,75(7):1322-1331.
[55] WU Y,LIU J,ZHENG Y,et al.Suppressed expression of long non-coding RNA HOTAIR inhibits proliferation and tumourigenicity of renal carcinoma cells[J].Tumour Biol,2014,35(12):11887-11894.
[56] CHIYOMARU T,FUKUHARA S,SAINI S,et al.Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells[J].J Biol Chem,2014,289(18):12550-12565.
[57] ZHANG H M,YANG F Q,YAN Y,et al.High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma[J].Int J Clin Exp Pathol,2014,7(9):5801-5809.
[58] QIAO H P,GAO W S,HUO J X,et al.Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma[J].Asian Pac J Cancer Prev,2013,14(2):1077-1082.
[59] YAO J,CHEN Y,WANG Y,et al.Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas[J].Int J Clin Exp Pathol,2014,7(6):2758-2767.
[60] MATTEI J,da SILVA R D,SEHRT D,et al.Targeted therapy in metastatic renal carcinoma[J].Cancer Lett,2014,343(2):156-160. |
